Background: The clinical information housed within unstructured electronic health records (EHRs) has the potential to promote cancer research. The National Cancer Center Hospital (NCCH) is widely recognized as a leading institution for the treatment of thoracic malignancies in Japan. Information on medical treatment, particularly the characteristics of malignant tumors that occur in patients, tumor response evaluation, and adverse events, was compiled into the databases of each NCCH department from EHRs. However, there have been few opportunities for integrated analysis of data on both the hospital and research institute.
Methods: We developed a method for predicting tumor response evaluation and survival curves of drug therapy from the EHRs of lung cancer patients using natural language processing. First, we developed a rule-based algorithm to predict treatment duration using a dictionary of anticancer drugs and regimens used for lung cancer treatment. Thereafter, we applied supervised learning to radiology reports during each treatment period and constructed a classification model to predict the tumor response evaluation of anticancer drugs and date when the progressive disease (PD) was determined. The predicted response and PD date can be used to draw a survival curve for the progression-free survival.
Results: We used the EHRs of 716 lung cancer treatments at the NCCH and structured data of the cases as labels for the training and testing of supervised learning. The structured data were manually curated by physicians and CRCs. We investigated the results and performance of the proposed method. Individual predictions of tumor response evaluation and PD date were not extremely high. However, the final predicted survival curves were nearly similar to the actual survival curves.
Conclusions: Although it is difficult to construct a fully automated system using our method, we believe that it achieves sufficient performance for supporting physicians and CRCs constructing the database and providing clinical information to help researchers find out a chance of clinical studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834625 | PMC |
http://dx.doi.org/10.1186/s12911-025-02928-6 | DOI Listing |
J Cell Mol Med
March 2025
Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University & Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.
View Article and Find Full Text PDFEur Urol
March 2025
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address:
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 receptor on T cells and a specific tumor antigen expressed on malignant cells, represent a promising therapeutic option. Multiple studies have explored the use of TCEs in previously treated patients with metastatic castration-resistant prostate cancer, and several ongoing trials are currently assessing novel TCEs either as single agents or in combinatorial regimens with molecules with a distinct mechanism of action (eg, androgen receptor pathway inhibitors and other immune-targeting agents).
View Article and Find Full Text PDFSci Bull (Beijing)
March 2025
State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Centre for New Organic Matter, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Centre for Analytical Sciences, College of Chemistry, School of Medicine and Frontiers Science Center for Cell Responses, Nankai University, Tianjin 300071, China. Electronic address:
Bull Cancer
March 2025
Oncologie médicale, Institut Curie, Paris, France.
Patients who develop Ewing sarcoma with extra-pulmonary metastasis have a poor prognosis. A recent French protocol, CombinaiR3, was set up to evaluate the efficacy of induction chemotherapy followed by high-dose chemotherapy and metronomic maintenance treatment. It is now closed for inclusions and while waiting for the results, we propose a French consensus guideline for the management of patients diagnosed with Ewing sarcoma with extra-pulmonary dissemination.
View Article and Find Full Text PDFJ Gastroenterol Hepatol
March 2025
Department of Radiology, Yunnan Cancer Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
This review provides an in-depth exploration of the evolving role of immunotherapy in gastrointestinal (GI) cancers, with a particular focus on immune checkpoint inhibitors (ICIs) and their associated predictive biomarkers. We present a detailed analysis of established biomarkers, such as PD-L1, microsatellite instability (MSI), tumor mutational burden (TMB), and the tumor microenvironment (TME), as well as emerging biomarkers, including gut microbiota and Epstein-Barr virus (EBV). The predictive value of these biomarkers in guiding clinical decision-making and optimizing immunotherapy outcomes is thoroughly discussed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!